NL-OMON27880已完成不适用
A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients wit relapsed or rogressive Waldenström’s macroglobiulinemia. A HOVON / Greek Myeloma Study Group study
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data Center-CTCErasmus MC P.O. box 2040NL- 3000 CA RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 72 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 72
研究概览
简要总结
none
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •A diagnosis of relapsed or progressive WM (lymphoplasmacytoid lymphoma in the bone marrow with an IgM M-protein)
- •Age ≥ 18 years
排除标准
- •Bortezomib refractory (no PR/CR after treatment with bortezomib, and/or progression within 6 months of treatment with bortezomib)
- •Rituximab refractory (progressive disease during treatment or within 6 months after last administration of rituximab)
研究者
相似试验
招募中
2 期
A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignancies2024-515119-23-00Transgene142
招募中
1 期
A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignanciesCTIS2024-515119-23-00Transgene142
进行中（未招募）
1 期
A study of TG4001 and avelumab cancer immunotherapies in advanced HPV-induced malignanciesHPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancerMedDRA version: 20.0Level: PTClassification code 10061424Term: Anal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10034299Term: Penile cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10046888Term: Vaginal cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10047777Term: Vulvar cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002799-28-GBTransgene52
进行中（未招募）
不适用
A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemiaPatients (age 18 or older) with relapsed or refractory chronic lymphocytic leukemia requiring treatmentMedDRA version: 12.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaMedDRA version: 12.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentMedDRA version: 12.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractoryEUCTR2009-012957-39-DEniversity of Cologne
进行中（未招募）
不适用
Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy.EUCTR2014-001620-29-ESGrupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)77